Peter J. Snyder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter J. Snyder has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Shalender Bhasin
Research Program in Men’s Health, Aging, and Metabolism, Brigham and Women’s Hospital, Harvard Medical School, Boston
5 shared publications- Kristine E. Ensrud
Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, USA
4 shared publications - Shalender Bhasin
Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115
4 shared publications Denise Cifelli
Center for Clinical Epidemiology & Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
3 shared publications- Glenn R. Cunningham
Baylor College of Medicine Medical Center, Houston, TX
3 shared publications Marco Pahor
Department of Aging & Geriatric Research, University of Florida, Gainesville, Florida
3 shared publications
Latest Publications
- 9 August 2025
- Published by Springer Nature
- p. 739-747
Testosterone Treatment of Late-Onset Hypogonadism: Benefits and Risks
- 9 August 2025
- Published by Springer Nature
- p. 739-747
Testosterone Treatment of Late-Onset Hypogonadism: Benefits and Risks
- Top Cited Papers
- 7 August 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 393 (6) , 581-591
Testosterone Treatment in Middle-Aged and Older Men with Hypogonadism
- 7 August 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 393 (6) , 581-591
Top Cited PapersTestosterone Treatment in Middle-Aged and Older Men with Hypogonadism
- Open Access
- 3 June 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (1) , 228-237
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine
Context Paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. Objective To evaluate the efficacy and safety of paltusotine in the treatment of patients with acromegaly previously controlled with injected somatostatin receptor ligands (SRLs). Methods This phase 3, randomized, double-blind, placebo-controlled trial enrolled adults with acromegaly who had insulin-like growth factor I (IGF-I) ≤1.0 times the upper limit of normal (×ULN) while receiving a stable dose of depot octreotide or lanreotide. Patients were switched from injected SRLs and randomized to receive paltusotine or placebo orally for 36 weeks. The primary endpoint was proportion of patients maintaining IGF-I ≤1.0×ULN. Secondary endpoints were change in IGF-I level, change in Acromegaly Symptom Diary (ASD) score, and maintenance of mean 5-sample growth hormone (GH) 999.99; P<.0001). Paltusotine was also superior to placebo for all secondary endpoints: mean (±SE) change in IGF-I of 0.04±0.09×ULN versus 0.83±0.1×ULN (P<.0001); mean (±SE) change in ASD score of –0.6±1.5 versus 4.6±1.6 (P=.02); mean GH maintained at P=.0003). The most common adverse events were acromegaly symptoms and gastrointestinal effects characteristic of SRLs. Conclusion Replacement of injected SRLs by once-daily oral paltusotine was effective in maintaining both biochemical and symptom control in patients with acromegaly and was well tolerated.
- 3 June 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (1) , 228-237
Open AccessAcromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine
Context Paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. Objective To evaluate the efficacy and safety of paltusotine in the treatment of patients with acromegaly previously controlled with injected somatostatin receptor ligands (SRLs). Methods This phase 3, randomized, double-blind, placebo-controlled trial enrolled adults with acromegaly who had insulin-like growth factor I (IGF-I) ≤1.0 times the upper limit of normal (×ULN) while receiving a stable dose of depot octreotide or lanreotide. Patients were switched from injected SRLs and randomized to receive paltusotine or placebo orally for 36 weeks. The primary endpoint was proportion of patients maintaining IGF-I ≤1.0×ULN. Secondary endpoints were change in IGF-I level, change in Acromegaly Symptom Diary (ASD) score, and maintenance of mean 5-sample growth hormone (GH) 999.99; P<.0001). Paltusotine was also superior to placebo for all secondary endpoints: mean (±SE) change in IGF-I of 0.04±0.09×ULN versus 0.83±0.1×ULN (P<.0001); mean (±SE) change in ASD score of –0.6±1.5 versus 4.6±1.6 (P=.02); mean GH maintained at P=.0003). The most common adverse events were acromegaly symptoms and gastrointestinal effects characteristic of SRLs. Conclusion Replacement of injected SRLs by once-daily oral paltusotine was effective in maintaining both biochemical and symptom control in patients with acromegaly and was well tolerated.
- Top Cited Papers
- 18 January 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 390 (3) , 203-211
Testosterone Treatment and Fractures in Men with Hypogonadism
Testosterone treatment in men with hypogonadism improves bone density and quality, but trials with a sufficiently large sample and a sufficiently long duration to determine the effect of testosterone on the incidence of fractures are needed. In a subtrial of a double-blind, randomized, placebo-controlled trial that assessed the cardiovascular safety of testosterone treatment in middle-aged and older men with hypogonadism, we examined the risk of clinical fracture in a time-to-event analysis. Eligible men were 45 to 80 years of age with preexisting, or high risk of, cardiovascular disease; one or more symptoms of hypogonadism; and two morning testosterone concentrations of less than 300 ng per deciliter (10.4 nmol per liter), in fasting plasma samples obtained at least 48 hours apart. Participants were randomly assigned to apply a testosterone or placebo gel daily. At every visit, participants were asked if they had had a fracture since the previous visit. If they had, medical records were obtained and adjudicated. The full-analysis population included 5204 participants (2601 in the testosterone group and 2603 in the placebo group). After a median follow-up of 3.19 years, a clinical fracture had occurred in 91 participants (3.50%) in the testosterone group and 64 participants (2.46%) in the placebo group (hazard ratio, 1.43; 95% confidence interval, 1.04 to 1.97). The fracture incidence also appeared to be higher in the testosterone group for all other fracture end points. Among middle-aged and older men with hypogonadism, testosterone treatment did not result in a lower incidence of clinical fracture than placebo. The fracture incidence was numerically higher among men who received testosterone than among those who received placebo. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).
- 18 January 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 390 (3) , 203-211
Top Cited PapersTestosterone Treatment and Fractures in Men with Hypogonadism
Testosterone treatment in men with hypogonadism improves bone density and quality, but trials with a sufficiently large sample and a sufficiently long duration to determine the effect of testosterone on the incidence of fractures are needed. In a subtrial of a double-blind, randomized, placebo-controlled trial that assessed the cardiovascular safety of testosterone treatment in middle-aged and older men with hypogonadism, we examined the risk of clinical fracture in a time-to-event analysis. Eligible men were 45 to 80 years of age with preexisting, or high risk of, cardiovascular disease; one or more symptoms of hypogonadism; and two morning testosterone concentrations of less than 300 ng per deciliter (10.4 nmol per liter), in fasting plasma samples obtained at least 48 hours apart. Participants were randomly assigned to apply a testosterone or placebo gel daily. At every visit, participants were asked if they had had a fracture since the previous visit. If they had, medical records were obtained and adjudicated. The full-analysis population included 5204 participants (2601 in the testosterone group and 2603 in the placebo group). After a median follow-up of 3.19 years, a clinical fracture had occurred in 91 participants (3.50%) in the testosterone group and 64 participants (2.46%) in the placebo group (hazard ratio, 1.43; 95% confidence interval, 1.04 to 1.97). The fracture incidence also appeared to be higher in the testosterone group for all other fracture end points. Among middle-aged and older men with hypogonadism, testosterone treatment did not result in a lower incidence of clinical fracture than placebo. The fracture incidence was numerically higher among men who received testosterone than among those who received placebo. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).
- 24 May 2023
- Published by Elsevier in Endocrine Practice
- Vol. 29 (9) , 723-726
Testosterone Treatment of Men with Unequivocal Hypogonadism Following Treatment of Organ-Confined Prostate Cancer
- 24 May 2023
- Published by Elsevier in Endocrine Practice
- Vol. 29 (9) , 723-726
Testosterone Treatment of Men with Unequivocal Hypogonadism Following Treatment of Organ-Confined Prostate Cancer
- 1 April 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 307 (2) , e221810
MRI Quantification of Cortical Bone Porosity, Mineralization, and Morphologic Structure in Postmenopausal Osteoporosis
Background Preclinical studies have suggested that solid-state MRI markers of cortical bone porosity, morphologic structure, mineralization, and osteoid density are useful measures of bone health. Purpose To explore whether MRI markers of cortical bone porosity, morphologic structure, mineralization, and osteoid density are affected in postmenopausal osteoporosis (OP) and to examine associations between MRI markers and bone mineral density (BMD) in postmenopausal women. Materials and Methods In this single-center study, postmenopausal women were prospectively recruited from January 2019 to October 2020 into two groups: participants with OP who had not undergone treatment, defined as having any dual-energy x-ray absorptiometry (DXA) T-score of -2.5 or less, and age-matched control participants without OP (hereafter, non-OP). Participants underwent MRI in the midtibia, along with DXA in the hip and spine, and peripheral quantitative CT in the midtibia. Specifically, MRI measures of cortical bone porosity (pore water and total water), osteoid density (bound water [BW]), morphologic structure (cortical bone thickness), and mineralization (phosphorous [P] density [31P] and 31P-to-BW concentration ratio) were quantified at 3.0 T. MRI measures were compared between OP and non-OP groups and correlations with BMD were assessed. Results Fifteen participants with OP (mean age, 63 years ± 5 [SD]) and 19 participants without OP (mean age, 65 years ± 6) were evaluated. The OP group had elevated pore water (11.6 mol/L vs 9.5 mol/L; P = .007) and total water densities (21.2 mol/L vs 19.7 mol/L; P = .03), and had lower cortical bone thickness (4.8 mm vs 5.6 mm; P < .001) and 31P density (6.4 mol/L vs 7.5 mol/L; P = .01) than the non-OP group, respectively, although there was no evidence of a difference in BW or 31P-to-BW concentration ratio. Pore and total water densities were inversely associated with DXA and peripheral quantitative CT BMD (P < .001), whereas cortical bone thickness and 31P density were positively associated with DXA and peripheral quantitative CT BMD (P = .01). BW, 31P density, and 31P-to-BW concentration ratio were positively associated with DXA (P < .05), but not with peripheral quantitative CT. Conclusion Solid-state MRI of cortical bone was able to help detect potential impairments in parameters reflecting porosity, morphologic structure, and mineralization in postmenopausal osteoporosis. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Bae in this issue.
- 1 April 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 307 (2) , e221810
MRI Quantification of Cortical Bone Porosity, Mineralization, and Morphologic Structure in Postmenopausal Osteoporosis
Background Preclinical studies have suggested that solid-state MRI markers of cortical bone porosity, morphologic structure, mineralization, and osteoid density are useful measures of bone health. Purpose To explore whether MRI markers of cortical bone porosity, morphologic structure, mineralization, and osteoid density are affected in postmenopausal osteoporosis (OP) and to examine associations between MRI markers and bone mineral density (BMD) in postmenopausal women. Materials and Methods In this single-center study, postmenopausal women were prospectively recruited from January 2019 to October 2020 into two groups: participants with OP who had not undergone treatment, defined as having any dual-energy x-ray absorptiometry (DXA) T-score of -2.5 or less, and age-matched control participants without OP (hereafter, non-OP). Participants underwent MRI in the midtibia, along with DXA in the hip and spine, and peripheral quantitative CT in the midtibia. Specifically, MRI measures of cortical bone porosity (pore water and total water), osteoid density (bound water [BW]), morphologic structure (cortical bone thickness), and mineralization (phosphorous [P] density [31P] and 31P-to-BW concentration ratio) were quantified at 3.0 T. MRI measures were compared between OP and non-OP groups and correlations with BMD were assessed. Results Fifteen participants with OP (mean age, 63 years ± 5 [SD]) and 19 participants without OP (mean age, 65 years ± 6) were evaluated. The OP group had elevated pore water (11.6 mol/L vs 9.5 mol/L; P = .007) and total water densities (21.2 mol/L vs 19.7 mol/L; P = .03), and had lower cortical bone thickness (4.8 mm vs 5.6 mm; P < .001) and 31P density (6.4 mol/L vs 7.5 mol/L; P = .01) than the non-OP group, respectively, although there was no evidence of a difference in BW or 31P-to-BW concentration ratio. Pore and total water densities were inversely associated with DXA and peripheral quantitative CT BMD (P < .001), whereas cortical bone thickness and 31P density were positively associated with DXA and peripheral quantitative CT BMD (P = .01). BW, 31P density, and 31P-to-BW concentration ratio were positively associated with DXA (P < .05), but not with peripheral quantitative CT. Conclusion Solid-state MRI of cortical bone was able to help detect potential impairments in parameters reflecting porosity, morphologic structure, and mineralization in postmenopausal osteoporosis. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Bae in this issue.
- 6 October 2022
- Published by Elsevier in Urologic Clinics of North America
- Vol. 49 (4) , 637-644
What We Have Learned from The Testosterone Trials
- 6 October 2022
- Published by Elsevier in Urologic Clinics of North America
- Vol. 49 (4) , 637-644
What We Have Learned from The Testosterone Trials
- 21 September 2022
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 51 (4) , 755-760
Symptoms of Late-Onset Hypogonadism in Men
- 21 September 2022
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 51 (4) , 755-760
Symptoms of Late-Onset Hypogonadism in Men
- 10 March 2022
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 23 (6) , 1151-1157
Testosterone treatment of late-onset hypogonadism – benefits and risks
As men age, their serum testosterone concentration falls, the total testosterone concentration barely but the free testosterone concentration more so. Testosterone treatment of older men who have low testosterone concentrations can ameliorate several consequences of this fall, including libido and sexual activity, distance walked, hemoglobin and volumetric bone mineral density and strength, but not vitality and cognitive function. The possibility that testosterone treatment of late-onset hypogonadism increases the risks of benign prostatic hyperplasia, prostate cancer or heart disease has been suggested but will not be determined until larger and longer trials are conducted.
- 10 March 2022
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 23 (6) , 1151-1157
Testosterone treatment of late-onset hypogonadism – benefits and risks
As men age, their serum testosterone concentration falls, the total testosterone concentration barely but the free testosterone concentration more so. Testosterone treatment of older men who have low testosterone concentrations can ameliorate several consequences of this fall, including libido and sexual activity, distance walked, hemoglobin and volumetric bone mineral density and strength, but not vitality and cognitive function. The possibility that testosterone treatment of late-onset hypogonadism increases the risks of benign prostatic hyperplasia, prostate cancer or heart disease has been suggested but will not be determined until larger and longer trials are conducted.